Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice-Reference-Cited by-同舟云学术

Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice

Published:2017-09-13 Issue:44 Volume:8 Page:77897-77914
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Faehling Martin¹,Schwenk Birgit¹,Kramberg Sebastian¹,Eckert Robert²,Volckmar Anna-Lena³,Stenzinger Albrecht³,Sträter Jörn⁴

Affiliation:

1. Department of Cardiology and Pneumology, Hospital Esslingen, Esslingen, Germany

2. Outpatient Cancer Treatment Clinic Esslingen, Esslingen, Germany

3. Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany

4. Institute of Pathology Esslingen, Esslingen, Germany

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients;Pharmaceuticals;2022-06-27

2. Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients;Diagnostics;2022-04-01

3. Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib;Pharmaceutical Research;2022-03-29

4. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report;Annals of Palliative Medicine;2022-03

5. Evolving trends in lung cancer: Epidemiology, diagnosis, and management;Indian Journal of Cancer;2022